Micheliolide and ACT001 as Covalent Modulators of Inflammation-Redox-Metabolism Networks in CNS Disorders: An Evidence-Stratified Review of Mechanisms and Translational Challenges.

Jing D, Chu H

Open source

DOI
10.2147/dddt.s644585
Published
2026
Container
Drug design, development and therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.2147/dddt.s644585,
  title = {Micheliolide and ACT001 as Covalent Modulators of Inflammation-Redox-Metabolism Networks in CNS Disorders: An Evidence-Stratified Review of Mechanisms and Translational Challenges.},
  author = {Jing D and Chu H},
  year = {2026},
  journal = {Drug design, development and therapy},
  doi = {10.2147/dddt.s644585},
  url = {https://doi.org/10.2147/dddt.s644585}
}

RIS

TY  - JOUR
TI  - Micheliolide and ACT001 as Covalent Modulators of Inflammation-Redox-Metabolism Networks in CNS Disorders: An Evidence-Stratified Review of Mechanisms and Translational Challenges.
AU  - Jing D
AU  - Chu H
PY  - 2026
JO  - Drug design, development and therapy
DO  - 10.2147/dddt.s644585
UR  - https://doi.org/10.2147/dddt.s644585
ER  - 

APA

D, J., & H, C. (2026). Micheliolide and ACT001 as Covalent Modulators of Inflammation-Redox-Metabolism Networks in CNS Disorders: An Evidence-Stratified Review of Mechanisms and Translational Challenges.. Drug design, development and therapy. https://doi.org/10.2147/dddt.s644585

Source records